Why the study?
Does adjuvant chemotherapy alter coagulation factors and platelet function in patients with Stage II breast cancer?
Population
49 patients with Stage II breast cancer receiving adjuvant chemotherapy
Design
Cohort
Authors
Loading...
Adjuvant chemotherapy may promote hypercoagulability in stage II breast cancer; leaves open need for prospective thrombotic risk studies.
Does adjuvant chemotherapy alter coagulation factors and platelet function in patients with Stage II breast cancer?
Adjuvant chemotherapy in Stage II breast cancer patients induces a significant decrease in thrombin time and partial prothrombin time, suggesting a hypercoagulable state.
Canobbio et al. (1986) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: